Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.

The purpose of this study was to evaluate in a phase I-II trial whether low doses of recombinant human interleukin 2 (rHuIL-2) over a prolonged period of time are safe and effective in eradicating or controlling minimal residual disease in children with neuroblastoma given high-dose chemotherapy (HD...

Descripción completa

Detalles Bibliográficos
Autores principales: Pession, A., Prete, A., Locatelli, F., Pierinelli, S., Pession, A. L., Maccario, R., Magrini, E., De Bernardi, B., Paolucci, P., Paolucci, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063104/
https://www.ncbi.nlm.nih.gov/pubmed/9716039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063104/
https://www.ncbi.nlm.nih.gov/pubmed/9716039

Ejemplares similares